Farnesoid X Receptor Agonists: A Promising Therapeutic Strategy for Gastrointestinal Diseases

被引：3
作者：
Almeqdadi, Mohammad [1 ]
Gordon, Fredric D. [2 ]
机构：
[1] Lahey Hosp & Med Ctr, Div Transplantat & Hepatobiliary Dis, Burlington, MA USA
[2] Tufts Med Ctr, Abdominal Transplant Inst, 800 Washington St,4 South, Boston, MA 02111 USA
来源：
GASTRO HEP ADVANCES | 2024年 / 3卷 / 03期
关键词：
FXR Agonists; Liver Disease; Bile Acids; Metabolic Effects; Immunomodulatory Effects; OBETICHOLIC ACID; NONALCOHOLIC STEATOHEPATITIS; NUCLEAR RECEPTOR; INDUCED AUTOPHAGY; LIVER; FXR; ETHANOL; TRANSPORTER; MULTICENTER; MICROBIOME;
D O I：
10.1016/j.gastha.2023.09.013
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Farnesoid X receptor (FXR) agonists have emerged as a promising therapeutic strategy for the management of various gastrointestinal (GI) diseases, including primary biliary cholangitis, nonalcoholic fatty liver disease, inflammatory bowel disease, alcohol-related liver disease, and primary sclerosing cholangitis. In this review, we discuss the mechanisms of action of FXR agonists, including their metabolic and immunomodulatory effects, and provide an overview of the clinical evidence supporting their use in the treatment of GI diseases. We also highlight the safety, adverse effects, and potential drug interactions associated with FXR agonists. While these agents have demonstrated efficacy in improving liver function, reducing hepatic steatosis, and improving histological endpoints in primary biliary cholangitis and nonalcoholic fatty liver disease, further research is needed to determine their long-term safety and effectiveness in other GI diseases, such as inflammatory bowel disease, alcohol-related liver disease, and primary sclerosing cholangitis. Additionally, the development of next-generation FXR agonists with improved potency and reduced side effects could further enhance their therapeutic potential.
引用
收藏
页码：344 / 352
页数：9
相关论文
共 70 条
  • [1] Anderson K.M., Gayer C.P., The pathophysiology of farnesoid X receptor (FXR) in the GI tract: inflammation, barrier function and innate immunity, Cells, 10, (2021)
  • [2] Jiao Y., Lu Y., Li X., Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis, Acta Pharmacol Sin, 36, pp. 44-50, (2015)
  • [3] Inagaki T., Choi M., Moschetta A., Et al., Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis, Cell Metab, 2, pp. 217-225, (2005)
  • [4] Zollner G., Wagner M., Moustafa T., Et al., Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-α/β in the adaptive response to bile acids, Am J Physiol Gastrointest Liver Physiol, 290, pp. G923-G932, (2006)
  • [5] Plass J.R.M., Mol O., Heegsma J., Et al., Farnesoid X receptor and bile salts are involved in transcriptional regulation of the gene encoding the human bile salt export pump: farnesoid X receptor and bile salts are involved in transcriptional regulation of the gene encoding the human bile salt export pump, Hepatology, 35, pp. 589-596, (2002)
  • [6] Landrier J.-F., Eloranta J.J., Vavricka S.R., Et al., The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-α and -β genes, Am J Physiol Gastrointest Liver Physiol, 290, pp. G476-G485, (2006)
  • [7] Denson L.A., Sturm E., Echevarria W., Et al., The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp, Gastroenterology, 121, pp. 140-147, (2001)
  • [8] Chen F., Ma L., Dawson P.A., Et al., Liver receptor homologue-1 mediates species- and cell line-specific bile acid-dependent negative feedback regulation of the apical sodium-dependent bile acid transporter, J Biol Chem, 278, pp. 19909-19916, (2003)
  • [9] Modica S., Gadaleta R.M., Moschetta A., Deciphering the nuclear bile acid receptor FXR paradigm, Nucl Recept Signal, 8, (2010)
  • [10] Biagioli M., Marchiano S., Carino A., Et al., Bile acids activated receptors in inflammatory bowel disease, Cells, 10, (2021)
1234567